GAJREE PHARMACY LIMITED

Risk Rating: LOW The company demonstrates a strong financial position with substantial net assets (£1.93m) and a healthy liquidity buffer, having consistently maintained positive working capital over the past several years. The primary risk factor is an administrative lapse regarding an overdue confirmation statement, but this does not currently indicate underlying financial distress. The business appears solvent and operationally stable based on the available historical data.

Key Concerns: * Regulatory Compliance Lapse: The company's confirmation statement is currently overdue. While this is often an administrative oversight, persistent failure to file can lead to Companies House penalties, potential striking off proceedings, and legal ramifications for the directors. * Increasing Leverage: Between 2023 and 2024, creditors falling due after more than one year increased significantly from £793,513 to £1,004,822. Concurrently, net assets saw a slight decline. This indicates the company is taking on more long-term debt, which requires monitoring to ensure debt service obligations remain comfortably covered by operational cash flows. * Concentrated Control: Mr. Pradeep Kumar Gajree holds over 75% of the shares, over 75% of the voting rights, and the right to appoint/remove directors. While typical for private family-run companies, this level of control creates inherent minority shareholder risk and concentrates key-man governance risk.

Positive Indicators: * Strong Solvency Position: Net assets have remained remarkably stable, hovering around the £1.9m to £2m mark for the past decade. Total assets (£3.08m) comfortably exceed total liabilities (£1m), indicating a robust equity base. * Healthy Liquidity: As of July 2024, current assets (£369,484) significantly exceed current liabilities (£149,569), resulting in net current assets of £219,915. The current ratio stands at approximately 2.47, suggesting the company can comfortably meet its short-term obligations. * Longevity and Stability: Incorporated in 1995, the company has nearly 30 years of operational history. Furthermore, the asset base is anchored by substantial fixed assets (£2.71m), which is typical for a property-holding/leasing business and provides tangible security against its long-term debts.

Due Diligence Notes: * Business Operations Discrepancy: The company is named "GAJREE PHARMACY LIMITED" but its registered SIC code is 68209 (Other letting and operating of own or leased real estate). Further investigation is required to determine if the pharmacy operations have ceased and the business has transitioned purely to a property-holding model, or if the pharmacy is operated from the owned real estate. * Long-Term Debt Terms: The nature and terms of the £1.004m in long-term creditors should be reviewed. Given the SIC code and the asset-heavy balance sheet, this is likely a commercial mortgage secured on the fixed assets. Verification of interest rates and maturity dates is necessary to assess future refinancing risk. * Confirmation Statement Rectification: It should be confirmed whether the overdue confirmation statement is merely a delay in filing or if there are unresolved disputes regarding the register of people with significant control (PSC) or share allocations. * Related Party Transactions: Given the family dynamics (Pradeep Kumar Gajree as director/secretary and Meena Gajree as director), related-party transactions, such as director loans or property leases to directors, should be scrutinized to ensure fair dealing and transparency.